POP Biotechnologies

POP Biotechnologies leverages its proprietary porphyrin-phospholipid (PoP) nanotechnology to create two primary platform solutions: the SNAP vaccine platform and Chemophototherapy for targeted oncology. The company is advancing a pipeline targeting infectious diseases, cancer, and chronic conditions like Alzheimer's, supported by significant non-dilutive funding from entities like the NIH and CEPI. As a private, platform-focused biotech, POP BIO partners with global health organizations and seeks collaborators to expand the application of its versatile nanoparticle technology.

Patented porphyrin-phospholipid (PoP) liposome platforms enabling two core technologies: 1) SNAP (Spontaneous Nanoliposome Antigen Particleization) for rapid, plug-and-play vaccine development, and 2) Chemophototherapy (CPT) for light-triggered, targeted delivery of chemotherapy to tumors.

In vaccines, POP BIO competes with other nanoparticle and VLP platforms from companies like Moderna (mRNA-LNPs), Novavax (protein nanoparticle), and numerous biotechs. Its differentiation lies in the simplicity and speed of the SNAP process. In targeted oncology, it competes with a wide array of drug delivery and triggered-release technologies from both large pharma and specialized biotechs.